The feasibility of measuring calprotectin from a throat swab as a marker of infections caused by group A streptococcus: a case-control feasibility study.

anti-bacterial agents antibiotics calprotectin group A streptococci leukocyte L1 antigen complex pharyngitis primary health care sore throat

Journal

BJGP open
ISSN: 2398-3795
Titre abrégé: BJGP Open
Pays: England
ID NLM: 101713531

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 20 06 2019
accepted: 23 07 2019
pubmed: 23 1 2020
medline: 23 1 2020
entrez: 23 1 2020
Statut: epublish

Résumé

Most people with sore throat do not benefit from antibiotic treatment, but nearly three-quarters of those presenting in primary care are prescribed antibiotics. A test that is predictive of bacterial infection could help guide antibiotic prescribing. Calprotectin is a biomarker of neutrophilic inflammation, and may be a useful marker of bacterial throat infections. To assess the feasibility of measuring calprotectin from throat swabs, and assess whether individuals with sore throats likely to be caused by streptococcal infections have apparently higher throat calprotectin levels than other individuals with sore throat and healthy volunteers. A proof of concept case-control study was undertaken, which compared primary care patients with sore throats and healthy volunteers. Baseline characteristics and throat swabs were collected from 30 primary care patients with suspected streptococcal sore throat, and throat swabs were taken from 10 volunteers without sore throat. Calprotectin level determination and rapid antigen streptococcal testing were conducted on the throat swab eluents. Calprotectin levels in the following groups were compared: volunteers without a sore throat; all patients with a sore throat; patients with a sore throat testing either negative or positive for streptococcal antigen; and those with lower and higher scores on clinical prediction rules for streptococcal sore throat. Calprotectin was detected in all throat swab samples. Mean calprotectin levels were numerically higher in patients with sore throat compared with healthy volunteers, and sore throat patients who had group A streptococci antigen detected compared with those who did not. Calprotectin can be measured from throat swab samples and levels are consistent with the hypothesis that streptococcal infection leads to higher throat calprotectin levels. This hypothesis will be tested in a larger study.

Sections du résumé

BACKGROUND BACKGROUND
Most people with sore throat do not benefit from antibiotic treatment, but nearly three-quarters of those presenting in primary care are prescribed antibiotics. A test that is predictive of bacterial infection could help guide antibiotic prescribing. Calprotectin is a biomarker of neutrophilic inflammation, and may be a useful marker of bacterial throat infections.
AIM OBJECTIVE
To assess the feasibility of measuring calprotectin from throat swabs, and assess whether individuals with sore throats likely to be caused by streptococcal infections have apparently higher throat calprotectin levels than other individuals with sore throat and healthy volunteers.
DESIGN & SETTING METHODS
A proof of concept case-control study was undertaken, which compared primary care patients with sore throats and healthy volunteers.
METHOD METHODS
Baseline characteristics and throat swabs were collected from 30 primary care patients with suspected streptococcal sore throat, and throat swabs were taken from 10 volunteers without sore throat. Calprotectin level determination and rapid antigen streptococcal testing were conducted on the throat swab eluents. Calprotectin levels in the following groups were compared: volunteers without a sore throat; all patients with a sore throat; patients with a sore throat testing either negative or positive for streptococcal antigen; and those with lower and higher scores on clinical prediction rules for streptococcal sore throat.
RESULTS RESULTS
Calprotectin was detected in all throat swab samples. Mean calprotectin levels were numerically higher in patients with sore throat compared with healthy volunteers, and sore throat patients who had group A streptococci antigen detected compared with those who did not.
CONCLUSION CONCLUSIONS
Calprotectin can be measured from throat swab samples and levels are consistent with the hypothesis that streptococcal infection leads to higher throat calprotectin levels. This hypothesis will be tested in a larger study.

Identifiants

pubmed: 31964636
pii: bjgpopen20X101006
doi: 10.3399/bjgpopen20X101006
pmc: PMC7330218
pii:
doi:

Types de publication

Journal Article

Langues

eng

Informations de copyright

Copyright © 2020, The Authors.

Références

Immunity. 2010 Nov 24;33(5):657-70
pubmed: 21094463
CMAJ. 2000 Oct 3;163(7):811-5
pubmed: 11033707
Inflamm Bowel Dis. 2013 Apr;19(5):1034-42
pubmed: 23470502
Am J Med. 2008 Dec;121(12):1099-106
pubmed: 19028207
Lancet Infect Dis. 2014 Mar;14(3):213-9
pubmed: 24440616
Cochrane Database Syst Rev. 2013 Nov 05;(11):CD000023
pubmed: 24190439
Acta Paediatr. 2010 Sep;99(9):1389-95
pubmed: 20412103
Bone Joint J. 2017 May;99-B(5):660-665
pubmed: 28455476
BMJ. 2002 Feb 23;324(7335):477-80
pubmed: 11859054
J Pediatr Gastroenterol Nutr. 2012 Nov;55(5):541-7
pubmed: 22699836
J Infect. 2015 Jun;71 Suppl 1:S101-5
pubmed: 25917806
J Public Health (Oxf). 2004 Sep;26(3):268-74
pubmed: 15454595
BMJ. 2010 May 18;340:c2096
pubmed: 20483949
Eur J Biochem. 1983 Jul 15;134(1):1-6
pubmed: 6861753
Am J Emerg Med. 2015 Oct;33(10):1436-9
pubmed: 26233616
Virus Res. 2013 Jan;171(1):1-7
pubmed: 23178588
BMJ. 2013 Oct 10;347:f5806
pubmed: 24114306
Clin Infect Dis. 2012 Nov 15;55(10):1279-82
pubmed: 23091044
CMAJ. 1998 Jan 13;158(1):75-83
pubmed: 9475915
Health Technol Assess. 2013 Nov;17(55):xv-xix, 1-211
pubmed: 24286461
J Antimicrob Chemother. 2014 Dec;69(12):3423-30
pubmed: 25091508
BMJ. 2002 Mar 2;324(7336):539-41
pubmed: 11872558

Auteurs

Behnaz Schofield (B)

Senior Research Fellow, Faculty of Health and Applied Sciences, University of West of England, Bristol, UK behnaz.schofield@uwe.ac.uk.

Clive Gregory (C)

Research Manager, School of Medicine Neuadd Meirionnydd, University Hospital of Wales, Cardiff, UK.

Micaela Gal (M)

Institute Translation Manager, School of Medicine Neuadd Meirionnydd, University Hospital of Wales, Cardiff, UK.

David Gillespie (D)

Deputy Director of Infection, Inflammation & Immunity Trials and Senior Research Fellow, Centre for Trials Research Neuadd Meirionnydd, University Hospital of Wales, Cardiff, UK.

Gurudutt Naik (G)

Honorary Clinical Lecturer, School of Medicine Neuadd Meirionnydd, University Hospital of Wales, Cardiff, UK.

Alastair Hay (A)

Professor of Primary Care, Centre for Academic Primary Care Bristol Medical School: Population Health Science, University of Bristol, Bristol, UK.

Nick Francis (N)

Professor of Primary Care Research, School of Medicine Neuadd Meirionnydd, University Hospital of Wales, Cardiff, UK.

Classifications MeSH